top of page
Glenn Hearson

Artificial intelligence to Control acute pulmonary Exacerbations in Cystic Fibrosis

We have recently commenced a new NIHR funded study led at Nottingham by Dr Helen Barr from the NIHR Nottingham BRC and the University of Nottingham.


ACE-CF (Artificial intelligence to Control acute pulmonary Exacerbations in Cystic Fibrosis)

Dr Helen Barr
Dr Helen Barr

1. What is the purpose of the study?

This study builds on previous studies (Project Breathe and SmartCareCF) that have looked at the data obtained from people with Cystic Fibrosis (CF) monitoring their health at home. This study progresses that work and uses Artificial Intelligence (AI) to predict when someone is at risk of developing a chest infection (exacerbation) before they develop symptoms that they are aware of. This means that they can potentially be treated sooner, may need less treatment and / or hospitals stays / clinic attendance.



The main purpose of this study is to establish if Breathe RM Signal app, which has been developed from these previous studies improves quality of life, reliably predicts when someone is becoming more unwell and is safe to use. Breathe RM Signal is a decision aid for patients. If the results are positive, we plan to make the technology available to all people with CF.

bottom of page